Images List Premium Download Classic

Erythropoietin

Erythropoietin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
Merck Sharp & Dohme Corp.
August 31, 2017 - N°20170247336

The present invention concerns compounds of formula i that inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 24, 2017 - N°20170240555

The present invention concerns a compound of formula i or a pharmaceutically acceptable salt thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
Merck Sharp & Dohme Corp.
August 24, 2017 - N°20170240513

The present invention concerns compounds of formula i that inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 17, 2017 - N°20170233412

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 10, 2017 - N°20170226120

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
Methods of treating cognitive impairment
University Of South Florida
July 06, 2017 - N°20170189490

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible ...
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Method for preparing recombinant glycoprotein having high sialic acid content, through glycosphingolipid synthesis cycle control
Korea Advanced Institute Of Science And Technology
May 11, 2017 - N°20170129932

The present invention relates to a method for preparing a recombinant cell line producing recombinant glycoproteins having a high sialic acid content by inhibiting glycosphingolipid (gsl) biosynthesis pathway in a cell line producing recombinant glycoproteins. Particularly, the present invention produces erythropoietin (epo), containing a high content of sialic acid in a cell, from a cell line, which induces cgt inhibition ...
Derivatisation of erythropoietin (epo)
Lipoxen Technologies Limited
May 04, 2017 - N°20170119893

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
Use of negative functional modulators of erythropoietin for therapy
Andremacon S.r.l.
April 27, 2017 - N°20170114132

The invention relates to negative functional modulators of erythropoietin (epo) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia a and b, von willebrand disease, angiodysplasia, proliferative disorders and neurological diseases ...
Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
Novagen Holding Corporation
April 27, 2017 - N°20170114110

A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic ...
Liquid pharmaceutical composition of conjugated erythropoietin
Intas Pharmaceuticals Ltd.
April 27, 2017 - N°20170112901

A liquid pharmaceutical composition having a conjugated erythropoietin, buffer, sugar, tonicity modifier and amino acid as an aggregation inhibitor. The liquid pharmaceutical composition provides a stable pharmaceutical composition which encompasses conjugated erythropoietin, acetate buffer, sucrose, arginine and sodium chloride which is maintained at a ph of about 4. 9 to 5. 3.
Tetrameric cytokines with improved biological activity
Ibc Pharmaceuticals, Inc.
March 02, 2017 - N°20170056516

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety. The ddd moieties form dimers that bind to the ad moieties, resulting in a 2:1 ratio ...
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel nitrogen-containing heteroaryl compounds and methods of use thereof
Fibrogen, Inc.
February 09, 2017 - N°20170035747

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
Compounds that bind to the erythropoietin receptor
Epodose Llc
February 02, 2017 - N°20170029481

The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin.
New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency ...
Epodose Llc
February 02, 2017 - N°20170027970

Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.
Anti-erythropoietin antibodies
Amgen Inc.
January 19, 2017 - N°20170015743

The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.
Method for purifying pegylated erythropoietin
Hoffmann-la Roche Inc.
January 12, 2017 - N°20170008941

Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a ...
Use of paricalcitol in the treatment of inflammatory anaemia
Hoffmann-la Roche Inc.
December 22, 2016 - N°20160367571

The present invention discloses the use of paricalcitol, a synthetic vitamin d analogue, in the treatment of inflammatory anaemia, preferably in combination with erythropoeisis-stimulating agents. The use of paricalcitol in the treatment of said pathology is associated with a reduced requirement for erythropoeisis-stimulating agents, with optimised iron absorption and with an increase in plasma erythropoietin levels in said patients. The ...
Purification of erythropoietin
F. Hoffmann-la Roche Ag
November 17, 2016 - N°20160333066

In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing calcium-ions and namely under conditions under which the ...
Vectors conditionally expressing protein
Intrexon Corporation
November 03, 2016 - N°20160317678

This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the ...
Loading